Vertex Pharmaceuticals (VRTX) News
NASDAQ: VRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
503.25-2.39 (-0.47%)
At close: Oct 8, 4:00 PM ET · Delayed 15 min
VRTX news summary
We found 31 recent headlines mentioning Vertex Pharmaceuticals (VRTX): 5 in the past week and 23 in the past 30 days, most often from Nasdaq, Seeking Alpha, Business Wire. For price context, VRTX is down 0.47% at $503.25. The most recent story, "QQQ, SPCX, QCOM, VRTX: ETF Outflow Alert", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Vertex Pharmaceuticals headlines
- QQQ, SPCX, QCOM, VRTX: ETF Outflow AlertLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco QQQ Trust (Symbol: QQQ) where we have detected an approximate…NasdaqQQQ, QCOM, VRTX
- Vertex to Announce Third Quarter 2026 Financial Results November 2ndBOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The…Business Wire
- Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in…NasdaqNVAX, VRTX
- Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowVertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.Nasdaq
- Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?Key PointsAmgen offers a diversified portfolio of established therapies across oncology and inflammation supported by robust cash flow.NasdaqAMGN, VRTX
- Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to KnowIn the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.Nasdaq
- Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?Key PointsAxsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders.NasdaqAXSM, VRTX
- Capital Group Global Growth Equity ETF Experiences Big OutflowLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Capital Group Global Growth Equity ETF (Symbol: CGGO) where we have…NasdaqCGGO, WDC, VRTX, SWKS
- Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A DowngradeSeeking Alpha
- 2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.Key PointsVertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property to maintain this dominance.Nasdaq
- 2 Healthcare Stocks That Just Delivered Great News for InvestorsKey PointsVertex Pharmaceuticals and Amgen recently posted strong clinical trial results for promising candidates.NasdaqVRTX, AMGN
- Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to KnowVertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day.Nasdaq
- Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.NasdaqVRTX, NVS, VERA
- CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?Key PointsCRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editing treatment, CASGEVY.NasdaqCRSP, VRTX
- Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking AlphaVRTX, BAC
- Vertex Posts Positive Phase II Data on Kidney Disease DrugVRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.NasdaqVRTX, ALDX, ACIU, PGEN
- Inaxaplin Shows Kidney Benefit In Additional Patient Groups As Vertex Completes Key Trial Enrollment(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) reported positive Phase 2b results for Inaxaplin in additional groups of patients with APOL1-mediated kidney disease (AMKD), while also announcing…Nasdaq
- Vertex reports positive mid-stage results of inaxaplin for kidney diseaseSeeking Alpha
- Notable ETF Inflow Detected - CGGO, WDC, VRTX, AONLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Capital Group Global Growth Equity ETF (Symbol: CGGO) where we have…NasdaqCGGO, WDC, VRTX, AON
- Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?Key PointsCRISPR Therapeutics will likely be a much larger company in 10 years.NasdaqCRSP, NVS, VRTX
- Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaVRTX, MS
- Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha
- Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha
- Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless ExecutionSeeking Alpha
- Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)Seeking Alpha
- Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth StorySeeking Alpha
- Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Vertex Pharmaceuticals Incorporated 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha
- Vertex To Acquire Crinetics For ~$10bn - What Investors Should KnowSeeking Alpha
- Vertex Pharmaceuticals Incorporated (VRTX) M&A Call TranscriptSeeking Alpha
- Vertex Pharmaceuticals Incorporated (VRTX) Crinetics Pharmaceuticals, Inc. - M&A Call - SlideshowSeeking Alpha